From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.

PubWeight™: 0.82‹?›

🔗 View Article (PMID 25956686)

Published in Exp Biol Med (Maywood) on May 07, 2015

Authors

Amelia E Firor1, Alexander Jares2, Yupo Ma3

Author Affiliations

1: Department of Pathology, Stony Brook University, Stony Brook, NY 11794, USA.
2: Department of Pathology, Stony Brook University, Stony Brook, NY 11794, USA Medical Scientist Training Program, Stony Brook University, Stony Brook, NY 11794, USA Graduate Program in Molecular and Cellular Pharmacology, Stony Brook University, Stony Brook, NY 11794, USA.
3: Department of Pathology, Stony Brook University, Stony Brook, NY 11794, USA yupo.ma@stonybrookmedicine.edu.

Articles cited by this

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96

Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63

Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19

The regulation of IL-10 production by immune cells. Nat Rev Immunol (2010) 9.18

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90

Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25

Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14

Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59

Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood (2010) 4.35

Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2004) 4.05

Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature (1986) 3.97

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29

Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res (1953) 3.14

Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A (2008) 3.14

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer (2006) 2.40

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood (2010) 2.31

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2.25

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol (2010) 2.24

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol (2004) 2.02

Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J Virol (2009) 1.62

The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J (2006) 1.62

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58

Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) (2011) 1.50

Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res (2010) 1.31

MAGE-A family: attractive targets for cancer immunotherapy. Vaccine (2011) 1.15

In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Sci Transl Med (2015) 1.10

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther (2008) 1.06

Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther (2009) 1.05

Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther (2014) 1.01

Immune checkpoint inhibitors in clinical trials. Chin J Cancer (2014) 0.98

The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med (Maywood) (2002) 0.94

Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines. Mutat Res (2005) 0.88

Graft-versus-host disease in experimental allogeneic bone marrow transplantation. Proc Soc Exp Biol Med (1991) 0.83

Immunotherapy of Friend disease in mice employing viable BCG vaccine. Proc Soc Exp Biol Med (1972) 0.82

Clinical application of adoptive T cell therapy in solid tumors. Med Sci Monit (2014) 0.82

Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice. J Immunother (2015) 0.80